Xingnaojing Combined with Brain Glycoside Peptide Targets LncRNA-H19 and Regulates hsa-microRNA (miR)-138-5p/MAPK6 to Alleviate Acute Ischemic Stroke

This study aimed to explore the efficacy of Xingnaojing combined with brain glycoside peptide (XCGP) in the treatment and prognosis of acute ischemic stroke (AIS). The expression levels of long non-coding RNA (lncRNA)-H19 and mitogen-activated protein kinase 6 (MAPK6) in 37 AIS patients were measured using quantitative reverse transcription polymerase chain reaction (RT-qPCR). The correlation between lncRNA-H19, microRNA (miR)-138-5p and MAPK6 was predicted using StarBase online software. In vitro and in vivo experiments were carried out using the ReNcell CX neural stem cell (NSC) line and an AIS rat model constructed by middle cerebral artery occlusion surgery, respectively. Following human ReNcell CX cell culture in a hypoxic environment, RT-qPCR was conducted to measure the expression levels of the related genes, MTT and WST-1 assays were performed to assess the proliferation and viability of ReNcell CX NSCs, and flow cytometry was utilized to assess ReNcell CX NSC apoptosis. In addition, the rotarod, beam walk, and adhesion removal tests were conducted to evaluate changes in the motility of rats with AIS, and the infarction volume was calculated. The results of RT-qPCR showed that lncRNA-H19 and MAPK6 were upregulated in AIS patients. The StarBase online software for the prediction of miRNA-target interactions showed that lncRNA-H19 targets miR-138-5p, which targets MAPK6 (P < 0.01 and P < 0.001, respectively). Further, human ReNcell CX cells that were administered XCGP displayed marked downregulation of MAPK6, and the AIS rat model with XCGP injection showed effective reduction in infarction volume, and notable recovery of motility (P < 0.01 and P < 0.001). XCGP may serve as a candidate for the treatment of AIS, thereby improving the ischemic status of ReNcell CX NSCs and the condition of rats with AIS.